Lexeo Therapeutics chief medical officer sells $10,410 in stock

Eric Adler, the Chief Medical (TASE:BLWV) Officer of Lexeo Therapeutics , Inc. (NASDAQ:LXEO), recently executed a sale of company shares. According to a recent SEC filing, Adler sold 2,359 shares of common stock on February 19, 2025, at an average price of $4.413 per share, totaling approximately $10,410. The transaction comes as LXEO trades near its 52-week low of $3.84, down significantly from its high of $19.50. InvestingPro analysis suggests the stock is currently undervalued. Following this transaction, Adler holds 68,266 shares in the company. The sale was conducted to cover tax obligations related to the release of restricted stock units. While the company maintains strong liquidity with a current ratio of 5.95, InvestingPro data reveals 13 additional key insights about LXEO’s financial health and market position, available in the comprehensive Pro Research Report.

In other recent news, Lexeo Therapeutics has announced the appointment of Dr. Kyle Rasbach as its new Chief Financial Officer. Dr. Rasbach brings extensive experience in life sciences and financial management, having previously held roles at Zentalis Pharmaceuticals, Eventide Asset Management, and T. Rowe Price. His appointment comes as Lexeo is preparing for significant advancements in its gene therapy programs. The CEO, R. Nolan Townsend, expressed optimism about Dr. Rasbach’s ability to contribute to the company’s mission of developing therapies for genetic conditions. Lexeo is currently focused on treatments for cardiovascular diseases and APOE4-associated Alzheimer’s disease. The company is utilizing a stepwise development approach, guided by early proof-of-concept data. It is important to note that Lexeo’s forward-looking statements are subject to risks and uncertainties, which are detailed in its filings with the U.S. Securities and Exchange Commission.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.